Recent blog posts
NCT07524335 Aspirin Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524335 Aspirin Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524335 clinical trial report covering Aspirin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07522151 Tegafur/Gimeracil/Oteracil Potassium Gastrooesophageal junction cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07522151 Tegafur/Gimeracil/Oteracil Potassium Gastrooesophageal junction cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07522151 clinical trial report covering Tegafur/Gimeracil/Oteracil Potassium, Phase 3, endpoints, sponsor, geography, readout timing and development whi
Read →
NCT07524972 Magnesium Sulfate Obstetric Labor, Premature Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524972 Magnesium Sulfate Obstetric Labor, Premature Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524972 clinical trial report covering Magnesium Sulfate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07525206 Telisotuzumab adizutecan Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07525206 Telisotuzumab adizutecan Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07525206 clinical trial report covering Telisotuzumab adizutecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07522996 Cyclosporine Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07522996 Cyclosporine Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07522996 clinical trial report covering Cyclosporine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07524257 Nogapendekin alfa inbakicept-pmln Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524257 Nogapendekin alfa inbakicept-pmln Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524257 clinical trial report covering Nogapendekin alfa inbakicept-pmln, Phase 3, endpoints, sponsor, geography, readout timing and development white
Read →
NCT07526792 SYS-6002 Urothelial Carcinoma of the Urinary Bladder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07526792 SYS-6002 Urothelial Carcinoma of the Urinary Bladder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07526792 clinical trial report covering SYS-6002, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07527078 GZR33 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07527078 GZR33 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07527078 clinical trial report covering GZR33, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07525219 Suzetrigine Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07525219 Suzetrigine Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07525219 clinical trial report covering Suzetrigine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261303 Pembrolizumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261303 Pembrolizumab KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261303 clinical trial report covering Pembrolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2031260049 Teriparatide Acetate( Asahi Kasei Pharma) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2031260049 Teriparatide Acetate( Asahi Kasei Pharma) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2031260049 clinical trial report covering Teriparatide Acetate( Asahi Kasei Pharma), Phase 3, endpoints, sponsor, geography, readout timing and de
Read →
NCT07528209 Oxaliplatin Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07528209 Oxaliplatin Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07528209 clinical trial report covering Oxaliplatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →